UiPath (NYSE:PATH) Trading Down 0.4%

UiPath Inc. (NYSE:PATH)’s stock price fell 0.4% on Thursday . The company traded as low as $18.88 and last traded at $19.17. 1,064,808 shares were traded during mid-day trading, a decline of 87% from the average session volume of 8,476,149 shares. The stock had previously closed at $19.24.

Wall Street Analysts Forecast Growth

Several analysts recently commented on PATH shares. Barclays raised their price objective on UiPath from $23.00 to $25.00 and gave the stock an “equal weight” rating in a research note on Friday, March 15th. Scotiabank lifted their price target on shares of UiPath from $29.00 to $30.00 and gave the company a “sector perform” rating in a research report on Thursday, March 14th. Mizuho boosted their price objective on shares of UiPath from $22.00 to $25.00 and gave the company a “neutral” rating in a research report on Thursday, March 14th. Bank of America boosted their target price on shares of UiPath from $26.00 to $30.00 and gave the stock a “buy” rating in a research note on Thursday, March 14th. Finally, BMO Capital Markets boosted their price objective on shares of UiPath from $24.00 to $28.00 and gave the stock a “market perform” rating in a research note on Thursday, March 14th. Nine equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $27.41.

UiPath Price Performance

The firm’s 50 day moving average is $21.91 and its 200 day moving average is $21.65. The firm has a market cap of $10.98 billion, a P/E ratio of -112.88 and a beta of 1.01.

UiPath (NYSE:PATH) last posted its quarterly earnings data on Wednesday, March 13th. The healthcare company reported $0.06 EPS for the quarter, topping the consensus estimate of ($0.04) by $0.10. UiPath had a negative net margin of 6.87% and a negative return on equity of 3.29%. The business had revenue of $405.25 million for the quarter, compared to analyst estimates of $383.32 million. As a group, analysts expect that UiPath Inc. will post -0.04 EPS for the current year.

Insiders Place Their Bets

In other UiPath news, CFO Ashim Gupta sold 40,000 shares of UiPath stock in a transaction dated Thursday, April 4th. The shares were sold at an average price of $21.66, for a total value of $866,400.00. Following the completion of the transaction, the chief financial officer now directly owns 660,762 shares of the company’s stock, valued at $14,312,104.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Over the last ninety days, insiders sold 72,000 shares of company stock valued at $1,591,360. Insiders own 31.03% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in PATH. Daiwa Securities Group Inc. increased its holdings in UiPath by 5.4% during the first quarter. Daiwa Securities Group Inc. now owns 25,400 shares of the healthcare company’s stock valued at $576,000 after buying an additional 1,300 shares during the last quarter. Greenwood Capital Associates LLC bought a new position in shares of UiPath in the first quarter worth approximately $235,000. Janney Montgomery Scott LLC boosted its position in shares of UiPath by 27.2% in the first quarter. Janney Montgomery Scott LLC now owns 89,340 shares of the healthcare company’s stock worth $2,025,000 after purchasing an additional 19,126 shares during the period. Smith Group Asset Management LLC bought a new position in shares of UiPath in the first quarter worth approximately $204,000. Finally, Private Advisor Group LLC boosted its position in shares of UiPath by 90.0% in the first quarter. Private Advisor Group LLC now owns 70,293 shares of the healthcare company’s stock worth $1,594,000 after purchasing an additional 33,306 shares during the period. 62.50% of the stock is owned by hedge funds and other institutional investors.

UiPath Company Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.